Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
805 people get ALNY articles and Market Currents by email alert.
Get email alerts on ALNY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (Tue, 4:00PM)
-
Business Wire (May 15, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 23, 2013)
-
-
-
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alnylam and Takeda Form Alliance In RNAiEben Tessari • Tue, May 27, 2008 -
-
-
-
-
-
-
-
-
-
-
7 Biotech Stocks Trading At Steep Discount To Target PriceKapitall • Thu, Nov 15, 2012 -
Casey Analyst Forecasts Explosive Biotech GrowthLife Sciences Report • Thu, Oct 11, 2012
-
-
-
-
-
China Biotech In Review: Deals, Trials And RegulationsChinaBio Today • Sun, Jul 15, 2012
-
-
-
-
-
Alnylam's CEO Discusses Q3 2012 Results - Earnings Call TranscriptMon, Nov 5, 2012 • 1 Comment
-
Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call TranscriptThu, Aug 5, 2010 • 2 Comments
-
Alnylam Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Business Wire (Tue, 4:00PM)
-
Business Wire (May 15, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 3, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
at CNBC.com (Feb 22, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 31, 2013)
-
Business Wire (Jan 16, 2013)
-
Business Wire (Jan 15, 2013)
-
Business Wire (Jan 14, 2013)
ALNY vs. ETF Alternatives
Company Description
Currently, there's no company description for ALNY.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, February 11, 11:00 AM Alnylam Pharmaceuticals (ALNY -3.4%) dips after MLV cut the shares to Hold from Buy. The firm says it prefers to take a cautious stance ahead of pending details of disease-modifying data from its lead partnered programs. One such program is its strategic alliance with The Medicines Co. (MDCO -3%) to develop ALN-PCS, an RNAi therapeutic program for the treatment of hypercholesterolemia. Comment! [Healthcare, On the Move]
- Thursday, January 17, 1:05 PM Alnyam Pharmaceuticals (ALNY -1.3%) slips on further dilution as the underwriters of its recent secondary offering exercise options to purchase an additional 1.2M shares at $20.13. The purchase increases the size of the offering from 8M to 9.2M and boosts the net proceeds to ALNY to $173.8M. Comment! [Healthcare, On the Move]
- Wednesday, December 12, 2012, 2:45 PM Alnylam Pharmaceuticals (ALNY +4%) trades up after Piper Jaffray raised its rating to Neutral and increased its price target from $19 to $25. Piper notes that with the Tekmira litigation behind them, ALNY can now focus more on clinical progress. Specifically, the firm expects the drug developer to have Phase II data on its ALN-TTR02 this summer to prepare for pivotal studies by year-end, adding that ALNY also plans to file applications with the FDA on sub-cutaneous hemophilia therapy formulations of ALN-TTR02 and ALN-AT3. Comment! [Healthcare, On the Move]
- Monday, December 10, 2012, 2:08 PM Alnylam Pharmaceuticals (ALNY +5.2%) trades up after reporting encouraging pre-clinical data for its RNAi therapeutic program to treat of hemophilia and other bleeding disorders. The drug candidate produced up to a four-fold increase in thrombin - a protein that plays a role in blood coagulation - in testing with non-human primates. The company says it eventually plans to have five different medications in clinical development by the end of 2015. Comment! [Healthcare, On the Move]
- Tuesday, November 13, 2012, 10:31 AM Alnylam Pharmaceuticals (ALNY +4.8%) is higher this morning after reaching a settlement with Tekmira Pharmaceuticals (TKMR +19.3%) resolving all litigation issues between the companies. It also signed a new licensing agreement that restructures the relationship and provides clarity on all intellectual property and licensing issues. As a result, TKMR will receive $65M within 10 days and is eligible to receive an additional $10M in near-term milestone payments in 2013. (Conference Call Webcast Replay) Comment! [Healthcare, On the Move]
- Tuesday, October 23, 2012, 3:06 PM Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY +0.2%) as its portion of the upfront fees in ALNY's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7M from Alnylam as a result of licenses that were supported by Isis' patents. 1 Comment [Healthcare, On the Move]
- Tuesday, August 28, 2012, 9:43 AM Monsanto (MON -0.4%) signs a deal with Alnylam Pharmaceuticals (ALNY +3.6%) to use the biopharma's gene-silencing technology to improve its biopesticides. MON gains exclusive rights to use ALNY's platform technology and intellectual property; ALNY will receive $29M in upfront payments plus milestone payments and research funding. Comment! [Commodities, On the Move]
- Monday, August 6, 2012, 4:16 PM Alnylam Pharmaceuticals (ALNY): Q2 EPS of -$0.25 misses by $0.04. Revenue of $20.9M (+1.5% Y/Y) in-line. Shares -4.7% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Monday, July 16, 2012, 11:47 AM Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial results for ALN-TTR02, a treatment for a genetic mutation of the transthyretin gene. The mutation causes a hereditary, systemic disease called ATTR, which can damage body organs and tissue such as the peripheral nerves and heart. Comment! [On the Move]
- Monday, July 16, 2012, 9:11 AM Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed ALN-TTR02, a potential treatment for a genetic mutation of the transthyretin gene, reduced serum TTR protein levels in a way that was "rapid, dose dependent, durable, and specific after just a single dose." Comment! [Healthcare, On the Move]
- Wednesday, February 15, 2012, 2:28 PM Off sharply on Tuesday after filing to sell 7M shares, Alnylam Pharmaceuticals (ALNY +14.7%) is more than recouping its losses after pricing its offering (increased to 7.5M shares) at $10.75. A high short interest (11.2% of float shorted as of Jan. 31) could be contributing to recent volatility. Comment! [Healthcare, On the Move]
- Monday, February 13, 2012, 5:06 PM Alnyam Pharmaceuticals (ALNY), which fell after reporting Q4 results last week, is down 4% AH after filing to sell 7M shares, worth $86.7M based on today's close. The company, less than a month removed from announcing a major restructuring plan, says it will use the proceeds to help advance its drug pipeline, including its ALN-TTR02 and ALN-APC drugs. Comment! [Healthcare, On the Move]
- Thursday, January 19, 2012, 6:31 PM Alnylam Pharmaceuticals (ALNY) announces a restructuring plan that will include a 33% reduction in the size of its workforce, with the goal of focusing on drugs aimed at treating amyloidosis and hemophilia. Analysts estimate Alnylam's 2011 revenue fell 17%, and expect its 2012 revenue to decline another 26.3%. Shares are currently halted. Comment! [Healthcare, On the Move]
- Wednesday, January 4, 2012, 9:52 AM Alynylam Pharmaceuticals (ALNY +3.3%) trades higher after the firm releases positive results from clinical tests of its cholesterol-reducing treatment. The firm says it will continue the study with increased dosages. Comment! [On the Move, Healthcare]
- Friday, October 14, 2011, 2:29 PM Alnylam Pharmaceuticals (ALNY +4.5%) gains after Rodman & Renshaw initiates the shares at market outperform on valuation, saying it has a clear technological lead and strongest patent position in the RNAi space." Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
Morning Coffee, Day Trading Watchlist: $AAPL $CRUS $ALNY | SharePlanner http://bit.ly/U0LMwD - View all 0 replies
-
- View all 0 replies
-
The Scientist
SRPT has superior RNA technology. ALNY has superior RNA delivery tech (via MIT collaboration). Acquire both and potential is limitless - View all 0 replies
-
- View all 7 replies
-
-
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!
-
Michael Bryant
Alnylam Pharmaceuticals (ALNY) has a nice chart. Looks a little like another rounded bottom. http://bit.ly/wZi3Vx - View all 0 replies
-
- View all 0 replies
-
David White
ALNY up approx. 50% since my article in early Dec. 2011. Love it when a call works well. - View all 0 replies
-
Jim Van Meerten
ALNY - 96% Barchart technical buy signal - 15 new highs and up 27.02% in the last month - Relative Strength Index 68.01% - View all 0 replies
LATEST REPLIES
-
- View all 7 replies
-
-
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!